Navigation Links
Nucletron, an Elekta company, installs Esteya for treating skin cancer in major US center
Date:12/13/2013

NEW YORK, Dec. 13, 2013 /PRNewswire/ -- The first Esteya® electronic brachytherapy system in the United States has been installed at New York's Memorial Sloan-Kettering Cancer Center. Esteya by Nucletron, an Elekta company, is a new approach for skin cancer treatment that relies on a small, high dose rate (HDR) X-ray source to apply high precision radiotherapy directly to the cancer site.

"With support from Elekta, Memorial Sloan-Kettering will lead a multicenter clinical study with the goal to further improve skin cancer treatment," says John Lapre, Executive Vice President, Elekta Brachytherapy. "With its leading role at the forefront of brachytherapy research, the hospital will help advance the quality of patient care and add to the evidence base that caregivers need for their clinical decisions."

Esteya features an efficient workflow, easy patient set-up, and a short, less than three-minute, treatment delivery. The system's compact design and reduced shielding requirements also make treatment with Esteya highly accessible, enabling clinicians to treat lesions virtually anywhere patients are seen in the clinic.

For more information about Esteya, visit www.esteya.com.

Availability of Esteya in identified markets is subject to regulatory approvals.

For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: johan.andersson@elekta.com  
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com 
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com.


'/>"/>
SOURCE Elekta
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nucletron, an Elekta Company, Receives U.S. FDA 510(k) Clearance for Esteya Electronic Brachytherapy System for Treating Skin Cancer
2. Nucletron, an Elekta company, to Debut New Flexitron Brachytherapy Afterloading Platform at 2013 American Brachytherapy Society Meeting
3. Elekta receives US FDA 510(k) clearance for its Monaco 5 treatment planning system
4. Elekta opens state-of-the-art radiotherapy training center in Beijing
5. Elekta appoints Niklas Savander as its next President and Chief Executive Officer
6. Private Hospital Group in Spain Expands Radiotherapy Capabilities with Countrys First Elekta Versa HD System
7. Elekta Announces Monaco 5.0 -- Comprehensive Radiation Treatment Planning Capabilities Brought Together in One System
8. New Elekta Radiation Therapy Technology Takes Weeks Off of Lung Cancer Treatments
9. Switzerlands Hopital Riviera Improves Confidence in Patient Treatment with Elektas Identify Solution
10. Elekta to Spotlight Versa HD System at 2013 ASTRO Annual Meeting
11. Elekta Introduces Groundbreaking Image Guidance Capabilities Integrated with Versa HD Cancer Treatment System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... December 2, 2016 On Thursday, the ... the Dow Jones Industrial Average edged 0.36% higher, to finish ... 0.35%. Losses were broad based as six out of nine ... research reports on the following Services equities: Myriad Genetics Inc. ... QGEN ), INC Research Holdings Inc. (NASDAQ: INCR ...
(Date:12/2/2016)... 2016 The concept of rare diseases and the ... this sector has been taking shape in Europe ... aspects and initiatives related to orphan medicinal products have been ... of member states individually. Many member states in the EU ... of orphan medicinal products, the result of which took the ...
(Date:12/2/2016)... 1, 2016 Around the corners of world, ... each habitable land present over earth. Cancer has become ... in a life time this is because of the ... now. Given the steady increase in global cancer incidence ... spiraling healthcare costs of treatment, there is increasing interest ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 03, 2016 , ... While James Earl Jones is known for myriad ... a show called "Front Page". One of the forthcoming episodes examines mammogram techniques; a ... plummeted in large part due to early detection. Like any other disease, treatments have ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients ... can now take advantage of a cosmetic procedure known as Carbon Dioxide ... reduces the appearance of age spots, fine lines, uneven coloration, wrinkles, scarring, ...
(Date:12/2/2016)... ... , ... Lori G. Cohen and Sara K. Thompson , ... American Conference Institute’s 21st Drug & Medical Device Litigation Conference , taking place ... conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation ...
(Date:12/2/2016)... AL (PRWEB) , ... December 02, 2016 , ... ... from across the Dothan-Wiregrass Area in Alabama are expected to attend the UNCF ... Schmitz, will help provide scholarship funds for area students and operating support to ...
(Date:12/2/2016)... ... ... The annual time frame to change Medicare health and prescription drug coverage, known ... Medicare beneficiaries who are looking to switch from their current plan to a Medicare ... during this period order for their new policy to go into effect in 2017. ...
Breaking Medicine News(10 mins):